Commercialization and market adoption risk
Revenue depends on clinicians adopting Nevisense and on successful launches of new applications.
- Scope
- Nevisense and Nevisense Go commercialization
- Materiality
- high
Scibase Holding
SciBase Holding AB is a Swedish medical technology group focused on dermatology diagnostics and early detection of skin disease. The company develops and commercializes Nevisense, a point-of-care platform that combines electrical impedance spectroscopy and AI to support clinicians in assessing suspicious skin lesions and related skin-barrier applications.
| % | |
|---|---|
| Diagnostic devices | 70% Point-of-care instruments and systems used to assess skin lesions and skin-barrier conditions. |
| Disposable electrodes and consumables | 20% Single-use components required to run the Nevisense diagnostic workflow. |
| Software and AI-enabled analysis | 5% Algorithmic and software elements that support diagnostic interpretation. |
| Services and collaboration revenue | 5% Commercial and development-related activities tied to partners and market access. |
SciBase sells primarily to dermatologists, skin cancer clinics, and other clinicians who evaluate suspicious lesions...
- Dermatology clinicsprimary
Buy Nevisense to support evaluation of suspicious skin lesions and improve diagnostic confidence.
- Skin cancer centersprimary
Use the platform in workflows focused on melanoma and nonmelanoma skin cancer detection.
- Research and collaboration partnerssecondary
Work with SciBase on new indications such as atopic dermatitis and skin-barrier applications.
- Hospitals and outpatient specialistssecondary
Adopt the device where point-of-care dermatology diagnostics can fit existing clinical pathways.
SciBase is headquartered in Stockholm and operates through a Swedish parent company with subsidiaries in the United...
- •Headquartered in Stockholm, Sweden
- •U.S. subsidiary supports American sales and marketing
- •German subsidiary supports a key European market
- •Commercialization spans regulated markets in the U.S. and EU
- •Foreign-currency exposure is mainly EUR, with growing USD exposure
SciBase’s strategy is centered on expanding clinical adoption of Nevisense and extending the platform into additional...
01
Broaden clinical and geographic commercializationmedium-term
The platform needs wider adoption to scale beyond niche use and support recurring demand.
02
Expand indications and product utilitymedium-term
New clinical uses can increase the addressable market and improve platform relevance.
03
Secure reimbursement and guideline supportlong-term
Clinical adoption is easier when the method is recognized in reimbursement systems and guidelines.
04
Improve manufacturing and supply-chain robustnessshort-term
Disposable electrodes and components must be available reliably for clinical use and scaling.
SciBase faces commercialization risk because its products depend on regulatory approval, reimbursement, and clinician...
Reimbursement and guideline risk
Without reimbursement or clinical guideline inclusion, adoption can remain limited.
- Scope
- Melanoma and skin-barrier indications
- Materiality
- high
Supply-chain and component availability risk
Electronic components and supplies are needed to manufacture and deliver devices and electrodes.
- Scope
- Manufacturing and customer deliveries
- Materiality
- high
Foreign exchange risk
The group reports in SEK but has exposure to EUR and future USD cash flows and balances.
- Scope
- EUR and USD transaction/translation exposure
- Materiality
- medium
Key-person dependence
The company relies on experienced personnel with product, partner, and market knowledge.
- Scope
- Management, R&D, and commercialization functions
- Materiality
- medium
Foreign currency translation
Affects reported equity, profit, and comparability across periods
IFRS 16
Lease accounting under IFRS 16
Changes leverage metrics and operating expense profile
Impairment of subsidiary investments
Can materially affect parent-company equity and profit
Estimates around commercialization costs and product development
Affects operating loss timing and period-to-period comparability
: 11/08/2026